공시 • Feb 05
Schott Pharma Ag & Co. Kgaa Approves Dividend SCHOTT Pharma AG & Co. KGaA announced that at the Annual General Meeting held on February 3, 2026, approved the proposed dividend of EUR 0.18 per share, which corresponds to a payout ratio of 18% of consolidated net income. Price Target Changed • Jan 12
Price target decreased by 9.8% to €20.72 Down from €22.97, the current price target is an average from 12 analysts. New target price is 32% above last closing price of €15.70. Stock is down 38% over the past year. The company is forecast to post earnings per share of €0.95 for next year compared to €0.97 last year. Price Target Changed • Dec 30
Price target decreased by 20% to €22.97 Down from €28.60, the current price target is an average from 13 analysts. New target price is 54% above last closing price of €14.94. Stock is down 40% over the past year. The company is forecast to post earnings per share of €0.95 for next year compared to €0.97 last year. Declared Dividend • Dec 30
Dividend increased to €0.18 Dividend of €0.18 is 13% higher than last year. Ex-date: 4th February 2026 Payment date: 6th February 2026 Dividend yield will be 1.2%, which is higher than the industry average of 0.5%. Sustainability & Growth Dividend is covered by both earnings (19% earnings payout ratio) and cash flows (77% cash payout ratio). The dividend has increased by an average of 9.5% per year over the past 2 years and payments have been stable during that time. EPS is expected to grow by 40% over the next 3 years, which should provide support to the dividend and adequate earnings cover. 공시 • Dec 22
SCHOTT Pharma AG & Co. KGaA, Annual General Meeting, Feb 03, 2026 SCHOTT Pharma AG & Co. KGaA, Annual General Meeting, Feb 03, 2026, at 10:00 W. Europe Standard Time. 공시 • Dec 12
SCHOTT Pharma AG & Co. KGaA announces Annual dividend, payable on February 06, 2026 SCHOTT Pharma AG & Co. KGaA announced Annual dividend of EUR 0.1800 per share payable on February 06, 2026, ex-date on February 04, 2026 and record date on February 05, 2026. 공시 • Dec 06
SCHOTT Pharma AG & Co. KGaA to Report Fiscal Year 2025 Results on Dec 04, 2025 SCHOTT Pharma AG & Co. KGaA announced that they will report fiscal year 2025 results at 5:30 PM, Central European Standard Time on Dec 04, 2025 공시 • Oct 09
SCHOTT Pharma AG & Co. KGaA to Report Fiscal Year 2026 Results on Dec 10, 2026 SCHOTT Pharma AG & Co. KGaA announced that they will report fiscal year 2026 results on Dec 10, 2026 공시 • Jun 13
SCHOTT Pharma Management AG Announces CFO Changes The Supervisory Board of SCHOTT Pharma Management AG has decided that CFO Dr. Almuth Steinkühler informed the Supervisory Board that she does not seek another term in office. She will leave SCHOTT Pharma at her own request after her current contract expires on July 31, 2025, to pursue new professional challenges. Reinhard Mayer will succeed Dr. Almuth Steinkühler on August 1, 2025. A graduate in industrial engineering, he looks back on many years of experience in corporate finance, controlling, and IT, including over 20 years in CFO positions. Mayer brings a wealth of perspectives from leading diverse global teams in multinational, publicly traded companies. In his most recent position as CFO of Denmark-listed Nilfisk Holding A/S, Mayer played a key role in shaping the company’s strategy for organic growth, overseeing financial consolidation and optimizing and digitizing business processes. Before that, he served as CFO on the Executive Board of Hansgrohe SE and spent 15 years in various global management positions, most recently as CFO at the Getinge Group, a publicly listed medical technology group based in Sweden. 공시 • Dec 19
SCHOTT Pharma AG & Co. KGaA, Annual General Meeting, Feb 04, 2025 SCHOTT Pharma AG & Co. KGaA, Annual General Meeting, Feb 04, 2025, at 10:00 W. Europe Standard Time. 공시 • Sep 05
SCHOTT Pharma AG & Co. KGaA to Report Fiscal Year 2024 Results on Dec 12, 2024 SCHOTT Pharma AG & Co. KGaA announced that they will report fiscal year 2024 results on Dec 12, 2024 Reported Earnings • Aug 30
Third quarter 2024 earnings: EPS and revenues exceed analyst expectations Third quarter 2024 results: EPS: €0.31 (up from €0.20 in 3Q 2023). Revenue: €253.6m (up 15% from 3Q 2023). Net income: €46.3m (up 52% from 3Q 2023). Profit margin: 18% (up from 14% in 3Q 2023). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 18%. Earnings per share (EPS) also surpassed analyst estimates by 52%. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Valuation Update With 7 Day Price Move • Aug 30
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to €36.18, the stock trades at a forward P/E ratio of 35x. Average forward P/E is 22x in the Life Sciences industry in Europe. Simply Wall St's valuation model estimates the intrinsic value at €46.51 per share. Reported Earnings • Jun 28
Second quarter 2024 earnings: EPS misses analyst expectations Second quarter 2024 results: EPS: €0.17. Net income: €25.0m (up €25.0m from 2Q 2023). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 18%. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Valuation Update With 7 Day Price Move • May 16
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to €31.78, the stock trades at a forward P/E ratio of 31x. Average forward P/E is 22x in the Life Sciences industry in Europe. Simply Wall St's valuation model estimates the intrinsic value at €47.63 per share. Reported Earnings • Mar 03
First quarter 2024 earnings released: EPS: €0.29 (vs €0.17 in 1Q 2023) First quarter 2024 results: EPS: €0.29 (up from €0.17 in 1Q 2023). Revenue: €232.3m (up 14% from 1Q 2023). Net income: €44.4m (up 74% from 1Q 2023). Profit margin: 19% (up from 13% in 1Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Life Sciences industry in Europe. Buy Or Sell Opportunity • Feb 29
Now 22% overvalued after recent price rise Over the last 90 days, the stock has risen 45% to €42.60. The fair value is estimated to be €35.03, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Earnings per share has grown by 20%. For the next 3 years, revenue is forecast to grow by 12% per annum. Earnings are also forecast to grow by 16% per annum over the same time period. Buy Or Sell Opportunity • Feb 01
Now 20% overvalued after recent price rise Over the last 90 days, the stock has risen 30% to €36.80. The fair value is estimated to be €30.65, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Earnings per share has grown by 20%. For the next 3 years, revenue is forecast to grow by 12% per annum. Earnings are also forecast to grow by 16% per annum over the same time period. 공시 • Sep 29
SCHOTT Pharma AG & Co. KGaA has completed an IPO in the amount of €813.318959 million. SCHOTT Pharma AG & Co. KGaA has completed an IPO in the amount of €813.318959 million.
Security Name: Ordinary Bearer Shares
Security Type: Common Stock
Securities Offered: 7,407,407
Price\Range: €27
Security Name: Ordinary Bearer Shares
Security Type: Common Stock
Securities Offered: 22,715,517
Price\Range: €27
Transaction Features: Regulation S; Rule 144A 
